NEW YORK, April 06, 2017 -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Pearson plc (“Pearson” or the “Company”) (NYSE:PSO) of the April 25, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.
The lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all those who purchased Pearson plc stock or options between January 21, 2016 and January 17, 2017 (the “Class Period”). The case, Chupka v. Pearson plc et al, No. 17-cv-01422 was filed on February 24, 2017, and has been assigned to Judge Richard J. Sullivan.
The lawsuit focuses on whether the Company and its executives violated federal securities laws by misrepresenting the future financial state of its U.S. education business through overly optimistic projections for years 2017 and 2018.
Specifically, in a press release published on January 18, 2017, Pearson announced that it would restructure its operative profit guidance for 2017 and 2018 due to an unprecedented decline in Q4 2016 in the Company’s North American higher education courseware business. The company also announced that it would rebase its dividend from 2017 onwards.
After the announcement, Pearson’s share price fell from $9.99 per share on January 17, 2017 to a closing price of $7.13 on January 18, 2017—a $2.86 or a 28.6% drop.
Request more information now by clicking here: www.faruqilaw.com/PSO. There is no cost or obligation to you.
Take Action
You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected].
Faruqi & Faruqi, LLP also encourages anyone with information regarding Pearson’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP 685 Third Avenue, 26th Floor New York, NY 10017 Attn: Richard Gonnello, Esq. [email protected] Telephone: (877) 247-4292 or (212) 983-9330


Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Samsung Electronics Shares Jump on HBM4 Mass Production Report
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



